1. Home
  2. EDAP vs NRSN Comparison

EDAP vs NRSN Comparison

Compare EDAP & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDAP
  • NRSN
  • Stock Information
  • Founded
  • EDAP 1979
  • NRSN 2017
  • Country
  • EDAP France
  • NRSN Israel
  • Employees
  • EDAP N/A
  • NRSN 15
  • Industry
  • EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • NRSN Biotechnology: Pharmaceutical Preparations
  • Sector
  • EDAP Health Care
  • NRSN Health Care
  • Exchange
  • EDAP Nasdaq
  • NRSN Nasdaq
  • Market Cap
  • EDAP 53.8M
  • NRSN 45.3M
  • IPO Year
  • EDAP 1997
  • NRSN 2021
  • Fundamental
  • Price
  • EDAP N/A
  • NRSN $1.91
  • Analyst Decision
  • EDAP Buy
  • NRSN Buy
  • Analyst Count
  • EDAP 3
  • NRSN 2
  • Target Price
  • EDAP $8.50
  • NRSN $14.00
  • AVG Volume (30 Days)
  • EDAP 37.5K
  • NRSN 427.0K
  • Earning Date
  • EDAP 08-27-2025
  • NRSN 07-15-2025
  • Dividend Yield
  • EDAP N/A
  • NRSN N/A
  • EPS Growth
  • EDAP N/A
  • NRSN N/A
  • EPS
  • EDAP N/A
  • NRSN N/A
  • Revenue
  • EDAP $67,840,467.00
  • NRSN N/A
  • Revenue This Year
  • EDAP N/A
  • NRSN N/A
  • Revenue Next Year
  • EDAP N/A
  • NRSN N/A
  • P/E Ratio
  • EDAP N/A
  • NRSN N/A
  • Revenue Growth
  • EDAP 3.69
  • NRSN N/A
  • 52 Week Low
  • EDAP $1.26
  • NRSN $0.51
  • 52 Week High
  • EDAP $5.28
  • NRSN $2.60
  • Technical
  • Relative Strength Index (RSI)
  • EDAP 36.07
  • NRSN 48.94
  • Support Level
  • EDAP $1.60
  • NRSN $1.81
  • Resistance Level
  • EDAP $1.74
  • NRSN $1.96
  • Average True Range (ATR)
  • EDAP 0.10
  • NRSN 0.20
  • MACD
  • EDAP -0.01
  • NRSN -0.08
  • Stochastic Oscillator
  • EDAP 27.59
  • NRSN 19.10

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Share on Social Networks: